|
Board of
Directors
M. Ann Abbe
Mathew Bergman, Esq.
Robert B. Cameron, M.D.
Michael Harbut, M.D., M.P.H.
Ulf Jungnelius, M.D.
Susan Vento
Nicholas J. Vogelzang, M.D.
Mouzetta Zumwalt-Weathers
Roger G. Worthington, Esq.
In Memoriam
Congressman Bruce F. Vento
Bill Powell
Science Advisory Board
Steven Albelda, M.D.
Raphael Bueno, M.D.
Raffit Hassan, M.D.
Steve Hahn, M.D.
Hedy Lee Kindler, M.D.
Dan Miller, M.D.
Harvey Pass, M.D., Chairman
Lary A. Robinson, M.D.
Victor Roggli, M.D.
W. Roy Smythe, M.D.
Robert N. Taub, M.D.
Joseph R. Testa, Ph.D.
Eric Vallieres, M.D.
Claire Verschraegen, M.D.
Executive Director
Christopher E. Hahn
MARF, inc.
1123 Chapala Street
2nd Floor
PO Box 91840
Santa Barbara, CA 93190-1840
tel: (805) 560-8942
fax: (805) 560-8962
http://www.marf.org
|

Our Mission is to eradicate mesothelioma as a
life-ending disease.
VIA E-MAIL, TELECOPY, and U.S. MAIL
January 21, 2005
The Honorable Arlen
Specter
Chairman, Senate Judiciary Committee
711 Hart Building
Washington, D.C. 20510
Re: Solution to Asbestos Public
Health Crisis
Dear Senator Specter:
As you have acknowledged, asbestos
disease in this country is a public health crisis. We the undersigned
are doctors and scientists who have expertise in the diagnosis,
causation, prevention and treatment of malignant mesothelioma, the
signature cancer for asbestos exposure. Mesothelioma is painful tumor
with a dismal prognosis, and our mission is to increase the funding of
the medical research that will, we believe, eventually solve the
problem.
On January 11, 2005, Billy Speicher, a
mesothelioma patient, implored his government to help find a cure. We
were pleased that in response you acknowledged that asbestos disease is
more than a litigation crisis and that the government should play a
leadership role in funding medical research. You indicated that you, as
a member of the Labor-HHS subcommittee, would look into how much of the
National Cancer Institute's nearly $5 billion budget is earmarked for
basic and applied research on mesothelioma.
We also looked into this question, and
here is what we found. From 2000 to 2003, the NCI spent on average $2.1
million per year on grants which use the word “mesothelioma” in their
abstract. This amount is far less than .1% of the NCI’s 2004 budget.
Unlike other cancers, the NCI does not even have a formal budget for
mesothelioma research, nor does it solicit grants relating to the
treatment or cure of mesothelioma. Mesothelioma kills between 3,000 and
4,000 Americans annually (the exact number is unknown since this country
does not have a nationwide registry unlike many others). Cervical
cancer, which has a similar mortality profile (viz., about 4,100 deaths
per year), in 2003 received $71.3 million from the NCI. To put those
numbers into perspective, the NCI allocated $17,340 for each cervical
cancer death, but only $933 per mesothelioma death. Clearly,
mesothelioma is under-funded when compared to other cancers.
Of the patients diagnosed with
mesothelioma every year, approximately 32% were exposed to asbestos
while serving in the U.S. Navy or while working in U.S. Navy shipyards.
However, neither the Department of Defense nor the Department of
Veterans Affairs has a program for the detection, prevention, treatment
or cure for mesothelioma. Meanwhile, Congress has since 1992
appropriated over $3.4 billion to the DOD for Congressionally Directed
Medical Research Programs (CDMRPs). A substantial portion of those
billions has been targeted for breast, ovarian and prostate cancer
research -- cancers that are not specific to military service.
Mesothelioma, on the other hand, is clearly a service-connected injury
for veterans who worked with and around asbestos.
We believe the Federal Government must
take the lead in solving the national tragedy of mesothelioma.
Mesothelioma has been a known occupational cancer for over 50 years.
Billions of dollars have been consumed by asbestos litigation, most of
which has been absorbed by transaction costs. Thousands of veterans and
civilians have already died as a result of asbestos diseases, and the
mortality rate for asbestos cancers is expected to climb over the next
10 years, as millions of tons of asbestos remain in place in schools,
buildings, homes and workplaces throughout the country, subjecting
millions of Americans to an increased risk of cancer. The asbestos
epidemic will continue to haunt us for decades, unless we take long
overdue curative action.
In 2002, MARF proposed a comprehensive
$140 million mesothelioma research and treatment program, which is 0.1%
of the projected value of the $140 billion federal asbestos trust
fund you are endorsing. The program addresses the public health program
at all levels: prevention, early detection, education, treatment and
cure. The program would foster collaboration between public and private
researchers, create nationwide treatment networks, promote and fund
innovative research, attract top scientific and medical talent, and
provide meaningful treatment options. In particular, the program would:
-
Establish a competitive peer
review grant program;
-
Fund Ten (10) Centers of
Mesothelioma Research/Treatment Excellence ($2.5M per year for five (5)
years);
-
Fund the Admiral Elmo Zumwalt
Registry and Clinical Database;
-
Fund the Congressman Bruce Vento
Blood & Tissue Bank; and
-
Target Research Priorities, which
include:
- Biomarkers for early
detection and prediction of recurrence;
- Biological therapies
(immunotherapy, gene therapy, novel chemotherapeutic compounds);
- Strategies for prevention
(inhibit pathways transforming normal to malignant cells); and
- Pain Management (mesothelioma
is an extremely aggressive and painful tumor).
The current version of the FAIR bill
incorporates only a portion of MARF's proposal. Unfortunately, the need
to fund medical research has always been drowned out by the often shrill
debate over who pays and how much. Because asbestos disease is a public
health crisis, and because the U.S. Government must play a leadership
role in solving the health problem, we believe present and future
asbestos disease patients are best served by a direct appropriation for
a CDMRP for mesothelioma. The need to alleviate the suffering, extend
survival, prevent needless death and create hope should not be tied to
the fortunes of an asbestos litigation reform bill, which historically
has failed to resonate with the American people in general and asbestos
victims in particular. Compensating victims does not in itself solve
the health crisis, and the two issues should be treated separately.
The
U.S. Government has a role and so does
industry, which for years mined, milled and processed the once
ubiquitous mineral fiber. As you have said repeatedly, since 2000, over
40 former asbestos companies have sought reorganization under Chapter
11 of the Bankruptcy Code. Experts project that the aggregate value
of all pending asbestos debtors’ settlement trusts will exceed $65 billion
(this number does not include the value of the 10-15 existing Chapter 11
asbestos debtor trusts). A substantial portion of the future trusts
will be siphoned off by management fees. Yet none of that money is
required to be set aside for peer-reviewed competitive research grants
to help alleviate the suffering of current claimants or extend the lives
of future claimants. We implore Congress to amend the Bankruptcy Code
to mandate that a reasonable percentage of existing and future asbestos
settlement trusts be allocated to a medical research trust, which will
target and fund meritorious research programs designed to detect,
prevent, treat and cure asbestos cancers. The former asbestos companies
will walk away from the bankruptcy courts, cleansed of their tort
liabilities, and leave behind a legacy of 27 million Americans with
dangerous levels of carcinogenic asbestos fibers in their lungs, fibers
which one day may generate lung cancer or mesothelioma, for which the
median survival at present is 12.3 months for those patients fortunate
enough to qualify for chemotherapy.
We believe we can find the Achilles heel
in mesothelioma. Even with limited funding, we have been able to make
meaningful improvements in the survival of mesothelioma patients. But
to declare victory against this terrible tumor which has exacted such a
heavy toll on Navy veterans, and which over the next 15 years will
likely rear its ugly head in the lung and abdominal linings of the brave
men and women who responded to the 9/11 terrorist attack at Ground Zero,
we cannot continue to rely on private donations alone. We need the
resources and the commitment of the U.S. Government. The Government has
the awesome power to replace despair with hope, nihilism with optimism,
defeatism with a can-do spirit, and rhetoric with action.
We
appreciate your efforts to help our patients survive the ravages of a
tumor that does not respect rank, power, age, sex, fame or political
affiliations. We would be pleased to meet with you and your staff to
articulate the details underlying MARF's proposals.
Sincerely,
Steven Albelda, M.D.
Vice Chief
and Director, Lung Research
University of Pennsylvania
Philadelphia, Pennsylvania |
Raphael Bueno, M.D.
Division
of Thoracic Surgery
Brigham & Womens Hospital
Boston, Massachusetts |
Robert B. Cameron, M.D.
Associate
Professor of Clinical Surgery
UCLA Medical Center
Los Angeles, California
|
| |
|
|
Steve Hahn, M.D.
Department
of Radiation Oncology
Philadelphia, Pennsylvania |
Michael Harbut, M.D.
Center for Occupational and
Environmental Medicine
Royal Oak, Michigan |
Hedy Lee Kindler, M.D.
University
of Chicago Medical Center
Section of Hematology/Oncology
Chicago,
Illinois |
| |
|
|
Ulf Jungnelius, M.D
Pfizer, Inc
Executive
Director
Oncology Clinical Development
New London, Connecticut |
Dan Miller, M.D.
Surgical
Director, Thoracic Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia |
Harvey Pass, M.D.
Professor
of Surgery and Oncology
Karmanos Cancer Institute
Detroit, Michigan |
| |
|
|
Lary A. Robinson, M.D.
Director,
Div. of Cardiovascular &
Thoracic Surgery
H. Lee Moffitt Cancer Center &
Research Institute |
Victor Roggli, M.D.
Professor
of Pathology, Duke University
and Virginia Medical Centers
Durham VA Medical Center
Durham, North Carolina |
W. Roy Smythe, M.D.
Professor & Chairman
Texas A&M
Univ. Health Sciences Ctr.
Scott & White Hospital and
Clinic
Department of Surgery
Temple, Texas |
| |
|
|
Daniel Sterman, M.D.*
Director,
Interventional Pulmonology Program
Clinical Director, Thoracic Oncology Gene
Therapy Program
Associate Professor of Medicine
in Surgery
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania |
Joseph R. Testa, M.D.
Cancer
Genetisist
Fox Chase Cancer Center
Philadelphia, Pennsylvania |
Eric Vallieres, M.D
Thoracic
Oncology
Swedish Cancer Institute
Seattle, Washington |
|
|
|
Claire Verschraegen, M.D.
Director
of Experimental Therapeutics
Cancer Research and Treatment Center
University of New Mexico
Albuquerque, New Mexico |
Nicholas J. Vogelzang, M.D.
Director,
Nevada Cancer Institute
Las Vegas, Nevada |
Bret Williams, M.D.
Mesothelioma Patient
Hillsborough, North Carolina |
* President, International Mesothelioma
Interest Group,
http://www.imig.org. The
International Mesothelioma Interest Group (IMIG) is a multinational
scientific organization composed of researchers, clinicians and others
dedicated to research into the causes and cures for Malignant
Mesothelioma.
| Cc: |
Senate Judiciary
Committee: |
|
|
| |
Sen. Saxby Chambliss
(R-GA)
Sen. John Cornyn (R-TX)
Sen. Larry Craig (R-ID)
Sen. Mike DeWine (R- OH)
Sen. Lindsey Graham (R-SC)
Sen. Charles E. Grassley (R-IA)
Sen. Jon Kyl (R-AZ)
Sen. Jeff Sessions (R-AL) |
|
Sen. Patrick J.
Leahy, Ranking Democratic Member, VT
Sen. Joseph R. Biden, Jr. (D-DE)
Sen. Richard J. Durbin (D-IL)
Sen. Russell D. Feingold (D-WI)
Sen. Dianne Feinstein (D-CA)
Sen. Edward M. Kennedy (D-MA)
Sen. Herbert Kohl (D-WI)
Sen. Charles E. Schumer (D-NY) |
| |
Sen. Harry
Reid (D-NV)
Sen. Patty Murray (D-WA) |
|
|
|